ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ADMA Biologics reports robust Q4 results and outlines growth strategies

ADMA Biologics demonstrated strong financial performance and strategic progress in Q4 2022, positioning the company for growth.
The company's focus on operational excellence, product performance, and market acceptance underpins its growth strategy.
Challenges in achieving profitability and market expansion are being addressed through strategic initiatives and operational enhancements.
Opportunities in label expansions, plasma donor targeting, and manufacturing scale-up offer avenues for sustained growth and market differentiation.

ADMA Biologics reports record revenue growth and profitability in Q1

ADMA Biologics demonstrated strong financial performance in Q1 2023, with notable revenue growth and achieving adjusted EBITDA profitability for the first time.
While facing regulatory and operational challenges, the company is strategically positioned for growth, focusing on immune globulin products and patient outcomes.
Management's commitment to innovation, cost efficiencies, and market expansion underscores ADMA's dedication to driving revenue growth and achieving profitability.

ADMA Biologics reports robust Q2 earnings and growth outlook

ADMA Biologics delivered strong financial results, raised revenue guidance, and showcased operational efficiency, positioning the company for sustained growth and market leadership.
The success of ASCENIV and the company's focus on plasma collection underscore ADMA's commitment to patient care, innovation, and social responsibility in the biologics sector.
While facing challenges in a competitive landscape, ADMA has opportunities to expand market reach, increase awareness, and solidify its position as a unique player in the industry.
By balancing financial objectives with social impact goals and emphasizing market differentiation, ADMA can navigate challenges and leverage opportunities for long-term success and stakeholder value.

ADMA Biologics achieves profitability in Q3, poised for growth

ADMA Biologics delivered a strong performance in Q3 2023, achieving profitability for the first time and demonstrating robust revenue growth.
The company's focus on ASCENIV, gross margin improvement, and revenue guidance raise optimism for future prospects and market positioning.
While facing challenges in debt refinancing and patient activation, ADMA Biologics is well-positioned to capitalize on opportunities in product enhancement and market expansion.
Overall, ADMA Biologics' strategic initiatives and financial performance in Q3 indicate a positive trajectory for growth and profitability in the biologics market.

ADMA Biologics achieves positive earnings, focuses on innovation and growth

ADMA Biologics reported a strong financial performance in Q4 2023, achieving positive adjusted net income and cash flow. The company emphasized innovation, growth strategies, and operational efficiencies to drive future success.
While facing challenges in managing profitability and debt, ADMA Biologics is focused on maintaining a strong gross margin profile and developing products targeting specific infectious diseases. The company's commitment to shareholder returns and revenue growth presents opportunities for sustained success.
Overall, ADMA Biologics showcased resilience and strategic planning during the earnings call, with a clear focus on financial stability, innovation, and maximizing shareholder value. The company's positive outlook and growth initiatives position it well for future growth and market competitiveness.

ADMA Biologics reports robust Q1 earnings, eyes sustained growth

ADMA Biologics delivered strong financial performance in Q1 2024, showcasing revenue growth, profitability, and upwardly revised guidance for 2024 and 2025, underlining their growth potential.
The company's focus on innovation, efficiency, and niche markets, along with confidence in long-term growth initiatives, positions them well for sustained value creation and revenue growth beyond 2025.
While facing challenges in operational efficiency, market penetration, and post-2025 revenue growth, ADMA Biologics remains optimistic about growth opportunities and revenue expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?

Geron

Lyra Therapeutics

Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presented in the paragraphs below.

3 'Buy-Rated' Biotech Stocks Under $10

In the most recent trading session, Adma Biologics (ADMA) closed at $6.04, indicating a -1.95% shift from the previous trading day.

Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note

Cimpress

H&E Equipment Services

360 Finance Inc - ADR

Willdan Group

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are QFIN, WLDN, HEES, CMPR, AIT.

5 Stocks With Recent Price Strength to Maximize Your Gain

Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now.

Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?

ADMA Biologics' stock has seen a significant rally, fueled by growth in plasma-derived biologics and improved financial health. Recent earnings highlight revenue growth, operational efficiencies, and a shift towards profitability, with notable progress in reducing operating expenses. Future growth is anticipated from Asceniv's market penetration and a promising pipeline, including a potential treatment for strep pneumonia.

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $6.29, denoting a +1.62% change from the preceding trading day.

Why the Market Dipped But Adma Biologics (ADMA) Gained Today

Betterware de Mexico

Modine Manufacturing

QuickLogic

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are QUIK, WLDN, BWMX, MOD and ADMA.

5 Stocks With Recent Price Strength With More Upside Left

ADMA Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Recent Price Trend in ADMA Biologics (ADMA) is Your Friend, Here's Why

The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Adma Biologics (ADMA) Could Surge 33.56%: Read This Before Placing a Bet

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?

FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life

ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®

Alight

The Nasdaq and the S&P 500 fell on Tuesday morning. The selling appeared unavoidable after the Nasdaq hit new highs late last week for the first time since the final months of 2021.

Finding Cheap Stocks Under $10 to Buy in March

Does Adma Biologics (ADMA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Adma Biologics (ADMA) Is Up 4.94% in One Week: What You Should Know

RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 6, 2024, at 11:35 a.m. ET.

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

First Bank

Griffon

Looking beyond profits to a company's cash position will be far more rewarding as this highlights its true financial health. Hence, GFF, HNI, ADMA and FRBA are worth buying.

4 Stocks With Increasing Cash Flows to Enrich Your Portfolio

The consensus price target hints at a 28.4% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Adma Biologics (ADMA) Could Rally 28.36%: Here's is How to Trade

ADMA Biologics, Inc. (ADMA) Q4 2023 Earnings Call Transcript

ADMA Biologics Announces CFO Transition

4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA ( 1 ) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income ( 2 ) of $8.5 Million; FY 2023 Adjusted Net Income of $0.7 Million FY 2024 and 2025 Total Revenue Guidance Increased to More Than $330 Million and $380 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $65 Million and Adjusted EBITDA Guidance Increased to More Than $90 Million FY 2025 Net Income Guidance Increased to More than $115 Million and Adjusted EBITDA Guidance Increased to More Than $140 Million Innovative Growth Opportunities Targeting Manufacturing and New Pipeline Hyperimmune Globulin to Advance During 2024 Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J.

ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes ADMA Successfully Utilized ADMAlytics' New Capabilities for the First Time to Automate and Realize Efficiency Improvements for Commercial Production Plasma Pooling Broader Implementation of ADMAlytics Expected to Provide Efficiencies Across the Organization RAMSEY, N.J. and BOCA RATON, Fla.

ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics

Affirm

Equitrans Midstream

Inhibikase Therapeutics

Orchid Island Capital

IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.

New Strong Buy Stocks for February 13th

Exelixis

HCA Healthcare

HCA Healthcare (HCA), ADMA Biologics (ADMA) and Exelixis (EXEL) are three medical stocks that you can look into as the sector continues to sustain its end-of-the-year momentum.

3 Medical Stocks to Buy as the Sector Continues to Grow

Adma Biologics (ADMA) closed at $5.18 in the latest trading session, marking a -1.71% move from the prior day.

News for ADMA Biologics Stock (ADMA)